After obesity drugs, baldness treatments ignite a new US stock market race
Translated from Korean and summarized by DistantNews. Read the original for the full story.
At a glance
News
From a news agency
Context piece
- Drugmakers are turning their attention to hair-loss treatments after obesity medicines fueled a record boom in the pharmaceutical industry.
- The hair-loss market has not seen a new drug since the late 1990s, while shares in companies developing new treatments have surged this year.
- US hair-loss drug developer Veradermics, listed on the New York Stock Exchange in February, has seen its share price rise nearly 500% in six months.
After obesity treatments produced an unprecedented boom for global drugmakers, investors are now chasing a new target: medicines for baldness.
The market has not received a new hair-loss drug since the late 1990s. That long gap has not stopped investors from betting heavily on companies developing the next generation of treatments.
Shares in related companies have climbed sharply this year, with some rising by as much as 500%. Veradermics, a US developer of hair-loss medicines that listed on the New York Stock Exchange in February, saw its stock price increase nearly fivefold in six months.
The surge reflects the pharmaceutical industry's growing interest in a treatment area that has remained without a new drug for decades.
About this summary
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.
More Stories
From Our Blog
What Gets Lost (and Found) When News Is Translated
The Critical Role of Diaspora Media in Global News
What Travellers Should Know About Countries with Restricted Press
A Digital Nomad's Guide to Following Local News
How the Same Story Looks Different in Different Countries
